MRKR Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Marker Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerMRKR

Market Cap25.7M

Cash RunwayRunway > 12 months

Next Catalyst2027-03

Public Research Snapshot

Marker Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for bevacizumab in genetic modifications (Phase 2) using Monoclonal Antibody.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Marker Therapeutics	genetic modifications	Cell Therapy	n/a	Public pipeline row
MT-601	n/a	n/a	Phase 1	Public pipeline row
Active Clinical Trials	n/a	Cell Therapy	n/a	Public pipeline row
bevacizumab	n/a	Monoclonal Antibody	Phase 2	Public pipeline row
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)	Limb Girdle Muscular Dystrophy \| Muscular Dystrophies	n/a	n/a	Public pipeline row
NEO-PV-01	Metastatic Melanoma	Vaccine	Phase 1	Public pipeline row
ELEVIDYS	Duchenne Muscular Dystrophy	n/a	Phase4	Public pipeline row
capsinoid supplementation	Obese Adolescents \| Exercise \| Diet Modification \| Dietary Supplement	n/a	Na	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-03	capsinoid supplementation	Low
		Clinical Trial Completion	2027-03-31	ELEVIDYS	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01656304	Phase 2	COMPLETED	16	2012-01
NCT03597282	Phase 1	TERMINATED	22	2020-05-05
NCT03981289	n/a	COMPLETED	116	2025-06-30
NCT06916208	Na	RECRUITING	38	2027-03
NCT07542314	Phase4	NOT_YET_RECRUITING	20	2027-03-31

Scientific Context

asset_name | Active Clinical Trials
modality | Cell Therapy
asset_name | Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
indication | Limb Girdle Muscular Dystrophy | Muscular Dystrophies
indication | Limb Girdle Muscular Dystrophy | Muscular Dystrophies

Want the full MRKR research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.